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ABSTRACT 
The objective of this research was to formulate fast dissolving tablet of amlodipine besylate 
for rapid action. Sublimation method was adapted to prepare the tablets by using a 2
3 full 
factorial design. FT-IR and D.T.A studies revealed that there was no physico-chemical 
interaction between amlodipine besylate and other excipients. All formulations are evaluated 
for pre-compression and post-compression parameters, wetting time, water absorption ratio. 
The results obtained showed that the quantity of starch potato, sodium starch glycolate, 
camphor significantly affect response variables. The results indicate that the optimized tablet 
formulation provides a short DT of 8 sec with sufficient crushing strength and acceptable 
friability. Stability studies of optimized formulation revealed that formulation is stable.
 
 
KEYWORDS: Amlodipine besylate, Camphor, Fast dissolving tablets, Sodium starch 
glycolate, Starch. 
1.  INTRODUCTION 
The concept of fast dissolving drug delivery system emerged from the desire to 
provide patient with conventional mean of taking their medication. Fast dissolving dosage 
forms can be disintegrated, dissolved, or suspended by saliva in the mouth. This fast 
dissolving tablet disintegrates instantaneously when placed on tongue and releases the drug 
dissolves or disperses in the saliva.
1 Fast dissolving tablets are useful in patients,
 2, 3 like 
pediatric, geriatric, bedridden, or mentally disabled, who may face difficulty in swallowing 
conventional tablets or capsules
4 leading to ineffective therapy,
 5   with persistent nausea, 
sudden episodes of allergic attacks, or coughing for those who have an active life style. Fast 
dissolving tablets are also applicable when local action in the mouth is desirable such as local 
anesthetic for toothaches, oral ulcers, cold sores, or teething,
 6  and to those who cannot 
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swallow intact sustained action tablets/capsules.
7
Angina pectoris, commonly known as angina, is chest pain due to ischemia of the 
heart muscle, generally due to obstruction or spasm of the coronary arteries (the heart's blood 
vessels).
8
The model drug selected was amlodipine besylate. Amlodipine besylate is chemically 
described as 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy) methyl] -4-(2-chlorophenyl)-1, 4-
dihydro -6-methyl-3, 5-pyridinedicarboxylate, mono benzenesulphonate monohydrate.
9 
Figure 1:  Structure of amlodipine besylate 
 
 
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-
channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth 
muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both 
dihydropyridine and non dihydropyridine binding sites. The contractile processes of cardiac 
muscle and vascular smooth muscle are dependent upon the movement of extra cellular 
calcium ions into these cells through specific ion channels. Amlodipine inhibits calcium ion 
influx across cell membranes selectively, with a greater effect on vascular smooth muscle 
cells than on cardiac muscle cells.
10 
 Generally, the following points are considered for patient compliance in case of anti-
angina patients, a rapid onset of action is necessary for immediate pain relief, patient has 
difficulty to swallow tablet or any another dosage form during pain, geriatrics has difficulty to 
swallow the dosage form. By considering the above points, patient convenience and 
compliance oriented research has resulted in bringing out safer and newer drug delivery 
systems one of such approach is fast dissolving drug delivery system. Conventional dosage 
forms for the anti-angina therapy includes tablets and injections. Injections provide effective 
rapid relief but, they are very painful and very expensive. 
In this study, an attempt has been made to formulate fast dissolving tablet formulations 
of amlodipine besylate by using a 2
3 factorial design by sublimation method.
11  The 
independent variables were selected as the quantities of starch potato, sodium starch glycolate 
(SSG) 
12, 13 and camphor, microcrystalline cellulose PH 102 (MCC) 
14 is used as diluent. 
Based on the preliminary studies, the ranges for formulation variables were selected. The 
dependent (response) variables were crushing strength, percentage friability and disintegration 
time (DT).  
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Camphor is a good subliming agent and in many formulations it is used as subliming 
agent.
14, 15 In sublimation method, SSG is used as disintegrant and camphor as subliming 
agent.
16
2.  MATERIALS AND METHODS 
2.1. Materials 
Amlodipine besylate, aspartame, sodium stearyl fumarate(SSF) were received as gift 
samples from Strides Arco Lab Pvt. Ltd, Bangalore, India. Microcrystalline cellulose PH-102, 
starch potato, sodium starch glycolate, orange flavor was supplied by BIO PLUS Pvt. Ltd. 
Bangalore, India. Other materials used were analytical grade. 
2.2. Experimental Design 
In the present study a 2
3 full factorial design was employed, containing 3 factors 
evaluated at 2 levels Table 1. The experimental trials were performed at 8 possible 
combinations and the three independent formulation variables evaluated included: 
A= Amount of Starch Potato 
B= Amount of Sodium Starch Glycolate 
C= Camphor  
Table 1: Level of formulation variables 
Independent variables   
Coded 
values 
starch (A) 
(mg) 
SSG (B) 
(mg) 
camphor (C) 
(mg) 
-1 
1 
19.2 
30.4 
8 
12.8 
8 
11.2 
 
2.3. Formulation by sublimation method:
  
In this study fast-dissolving tablet were prepared by using camphor. Eight 
formulations of Amlodipine besylate containing camphor
17, 18 in different proportions were 
prepared by using MCC (PH102) as a diluent.  All the ingredients were passed through # 60 
mesh separately. The drug and the diluents was mixed in small portion of both each time and 
blending it to get uniform mixture and set aside. The other ingredients were weighed and 
mixed in geometrical order. Flavouring agent was added at the end and then mixed 
thoroughly with lubricant. The tablets of weight 160 mg were prepared by direct compression 
technique using 7 mm punch in 10-station rotary machine; Remake Minipress, Ahmedabad 
and the tablets are subjected to sublimation to attain the constant weight which indicates the 
complete removal of subliming agent. The composition of the factorial design batches is 
shown in Table 2.  
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Table 2: Formulation of amlodipine besylate tablets 
INGREDIENTS Starch SSG Camphor 
F1(mg) 19.2  12.8  11.2 
F2(mg) 30.4  12.8  11.2 
F3(mg) 19.2  8  11.2 
F4(mg) 30.4  8  11.2 
F5(mg) 30.4  8 8 
F6(mg) 19.2  12.8  8 
F7(mg) 19.2  8 8 
F8(mg) 30.4  12.8  8 
FSP(mg) 20.97  12.8  9.07 
 
3.  COMPATIBILITY STUDIES 
3.1. Fourier Transform Infrared Spectroscopy (FT-IR): 
FT-IR spectroscopy was carried out for the following a) pure drug amlodipine besylate 
b) amlodipine besylate with starch c) amlodipine besylate with SSG d) amlodipine besylate 
with camphor e) amlodipine besylate with MCC f) amlodipine besylate with aspartame g) 
amlodipine besylate with aerosil h) amlodipine besylate with sodium stearyl fumarate (SSF) 
using Shimadzu FTIR model 8300 by taking KBr disc. 
3.2. DIFFERENTIAL THERMAL ANALYSIS (DTA): 
Amlodipine besylate and excipients were weighed and sealed in 40 ml aluminum 
crucibles with a pierced aluminum lid. Differential thermal analysis thermograms were 
obtained using a Mettler-Toledo STAR system and the DSC 822/700/1089 module (calibrated 
with indium). The analyses were performed under nitrogen (nitrogen flow rate 50 ml/min) in 
order to eliminate oxidative and pyrrolytic effects at a standard heating rate of 15ºC/minute 
over a temperature range of 30ºC - 300ºC.  The melting range and other transitions of the drug 
substance and the individual excipient were determined previously and the representative 
thermograms were retained for comparison with the thermograms of mixtures.  
DTA was carried out for the following a) pure drug amlodipine besylate b) amlodipine 
besylate with starch c) amlodipine besylate with SSG d) amlodipine besylate with camphor e) 
amlodipine besylate with MCC using a Mettler-Toledo STAR system
4.  3. EVALUATION PARAMETERS 
4.1. Pre-compression Parameters  
4.1.1.  Flow properties 
The tablet blends were evaluated for their bulk density, tapped density, carr’s index 
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and flow properties. The tapping method was used to determine the tapped density, bulk 
density and percent carr’s index.  
4.2. Post-compression Parameters  
4.2.1.  Tablet Hardness
 
The strength of tablet is expressed as tensile strength (Kg/cm
2). The tablet crushing 
load, which is the force required to break a tablet into pieces by compression. It was measured 
using a tablet hardness tester (Monsanto hardness tester).
19 
4.2.2.  Weight Variation Test 
Randomly selected 20 tablets were weighed individually and together in a single pan 
balance. The average weight was noted and standard deviation was calculated. IP limit for 
weight variation in case of tablets weighting up to 120 mg is ± 10%, 120 mg to 300 mg is ± 
7.5% and more than 300 mg is ± 5%. 
PD= (Wavg) – (W initial) / (W avg) x 100 
Where PD= Percentage deviation,  
Wavg = Average weight of tablet,  
Winitial = Individual weight of tablet. 
4.2.3.  Friability 
Roche friabilator was used for the purpose. This device subjects a number of tablets to 
the combined effect of abrasion and shock by utilizing a plastic chamber that revolves at 25 
rpm dropping the tablets at a distance of 6 inches with each revolution. Pre-weighed 20 tablets 
were placed in the friabilator, which was then operated for 100 revolutions. Tablets were 
dusted and reweighed.  
4.2.4.  Drug Content 
Ten tablets were powered and the blend equivalent to 5 mg of amlodipine besylate was 
weight and dissolved in suitable quantity of pH 1.2 solutions. Solution was filtered and 
diluted and drug content analyzed spectrophotometrically at 239 nm using Shimadzu 
Corporation, UV-1601, Japan. 
4.2.5.  Disintegration Time
 
The disintegration time of tablet was measured in water (37
0C) according to USP 
disintegration test apparatus. Three trials for each were performed.
17
4.2.6.  Wetting Time and Water Absorption Ratio 
A piece of tissue paper folded twice was kept in a culture dish (internal diameter 5.5 
cm) containing 6 ml of purified water. A tablet having a small amount of amaranth powder on 
the upper surface was placed on the tissue paper. The time required to develop a red color on 
the upper surface of the tablet was recorded as the wetting time. The same procedure without 
amaranth was followed for determining the water absorption ratio.
20 The wetted tablet was 
weighed and the water absorption ratio, R, was determined according to the following 
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equation,
  
R = 100 (W a - W b)/W b
Where, Wb and Wa were the weights of the tablet before and after study. 
4.2.7.  In vitro dispersion time
 
In vitro dispersion time was measured by dropping a tablet in a beaker containing 50 
ml of Sorenson's buffer pH 6.8. Three tablets from each formulation were randomly selected 
and in vitro dispersion time was performed.
21, 22 
4.2.8.  Dissolution Studies of Formulated Tablets
 
The dissolution of amlodipine besylate tablets was carried out in basket type 
dissolution apparatus. The dissolution medium, 500 ml of 0.1 N HCL was taken and 
temperature is maintained at 37±1
0C.
 The basket was rotated at 75 rpm for 30min.
23 The 
sample of 10 ml was withdrawn after every 5 min. and its absorbance was measured at 239 
nm. 
5.  Results and discussion 
5.1. Compatibility Studies 
The FT-IR studies revealed that amlodipine besylate is compatible with the excipients 
used in the formulation. There were no extra peaks observed in the IR spectrum. The IR 
absorption band in cm
-1 of the drug and excipients was found to be similar. This established 
that the drug amlodipine besylate and all the excipients used in the study showed no 
interaction and indicated that they were compatible with each other Table 3.  
Table 3 FT-IR studies of amlodipine besylate alone and with excipients 
  
COMBINATIONS 
AMINE 
GROUP 
(cm
-1) 
ETHYLESTE
R OF ARYL 
ACID (cm
-1) 
SULFONIC  
SALTS  (cm
-1) 
ALIPHATIC 
ETERS (cm
-1) 
PURE DRUG  3194.23  1303.92  1184.33  1122.61 
DRUG WITH SSG  3152.11  13.25.01  1168.9  1120.68 
DRUG WITH 
CAMPHOR  3108.21 1356.02  1156.06  1125.11 
DRUG WITH MCC  3155.65  1303.92  1178.55  1118.75 
DRUG WITH 
ASPARTAME  3118.02 1329.15  1158.31  1114.25 
DRUG WITH 
AEROSIL 3125.16  1345.02 1165.13 1109.21 
DRUG WITH SSF  3130.22  1335.21  1155.15  1125.07 
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In DTA, the chemical and physical changes of the substance are recorded as a function 
of temperature or time as substance is heated at a linear rate. DTA is useful in investigation of 
solid state interaction. In DTA, Thermograms are generated for the pure component and their 
physical mixture. In the absence of the any interaction, thermogram of mixture shows patterns 
corresponding to those of the individual components. DTA studies also revealed that 
amlodipine besylate is compatible with the excipients used in the formulation Figure 2.  
Figure 2: D.T.A of amlodipine besylate and with excipients A) Pure drug, B) Drug 
with SSG, C) Drug with MCC and D) Drug with camphor 
 
5.2. Pre-compression Parameters  
Powders were prepared by using sublimation method having good flow properties and 
good compressibility index as indicated in Table 4. 
Table 4. Pre compression Parameters of granules of Amlodipine Besylate by Sublimation 
Method 
 
Formula 
tions 
BULK 
DENSITY 
(g/ml) 
TAPPED  
DENSITY(g/ml)
ANGLE 
OF  
REPOSE 
(o) 
MEAN 
CARR’S 
INDEX 
HAUSNER'S
 RATIO 
F1  0.467 ± 0.29  0.5914 ± 0.19  30.6 ±0.28 21.9 ±0.13  1.26±0.16 
F2  0.478 ±0.32  0.598 ± 0.27  29.1 ±0.25 20 ± 0.17  1.25±0.17 
F3  0.447 ± 0.39  0.573 ± 0.32  29.7 ±0.23 21.9 ±0.23  1.28±0.14 
F4  0.469 ± 0.25  0.59 ± 0.19  29.3 ±0.23 20.5 ±0.31  1.25±0.14 
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F5  0.469 ± 0.27  0.577 ± 0.39  27.7 ±0.35 18.5 ±0.33  1.23±0.12 
F6  0.449 ± 0.31  0.555 ± 0.15  27.3 ±0.25 18.9 ±0.41  1.23±0.16 
F7  0.465 ± 0.42  0.552 ± 0.27  26.4 ±0.55 15.7 ±0.28  1.18±0.13 
F8  0.472 ± 0.4  0.589 ± 0.3  29.6 ±0.43 19.8 ±0.09  1.24±0.19 
FSP  0.470 ± 0.16  0.60 ± 0.22  27.2 ±0.09 21.6±0.31  1.27±0.07 
 
5.3. Post compression Parameters  
The hardness of the tablet was found between 3.0 - 4.5 kg/cm
2 which have good 
mechanical strength. The tablet thickness was found to be 3.1-3.25 mm, weight variation the 
average percentage deviation of 20 tablets of each formula was less than ±7. 5% Table 5, 
which provided good uniformity, friability of tablet was found below 1% indicating good 
mechanical resistance. The drug content found in the range of 97-102% (acceptable limit), 
disintegration time of all batches was found in the range of 6.5 – 9.7 sec. The wetting time of 
formulated tablets was found in the range of 9.3 – 22.5sec, water absorption ratio 77.5 – 
83.1% , In vitro dispersion time 15.2 – 24 s,%CDR 96.0% - 97.7%  and the %CDR of 
optimized formulation was compared with marketed product Figure 3. 
Figure 3: Comparison of dissolution profiles of optimized formula (FSP) with marketed 
product 
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Table 5. (a) Post Compression Parameters of Tablets (F1 – F4) of Sublimation Method 
Parameters  F1 (mg)   F2 (mg)  F3 (mg)  F4 (mg) 
Weight Variation  0.603 ± 0.011  0.600 ± 0.009  0.602 ± 0.010  0.601 ± 0.135 
Thickness (mm)  3.25 ± 0.07  3.2 ± 0.19  3.25 ± 0.14  3.25 ± 0.2 
Hardness (kg/cm2)  3 ± 0.09  3.5 ± 0.14  3 ± 0.12  3.75 ± 0.32 
Friability (%w/w)  0.42 ± 0.21  0.3 ± 0.25  0.4 ± 0.13  0.28 ± 0.14 
Disintegration time (sec)  6.52 ± 0.08  6.9 ± 0.21  7.2 ± 0.22  7.81 ± 0.14 
Wetting time (sec)  9.3 ± 0.11  11.3 ± 0.32  12.5 ± 0.29  16.1 ± 0.21 
Water absorption ratio 
(%)  82.3 ± 0.16  83.1 ± 0.21  81.6 ± 0.1  82 ± 0.15 
In Vitro Dispersion Time 
(sec)  15.2 ± 0.07  15.8 ± 0.2  15.4 ± 0.16  17.8 ± 0.19 
%Drug content  97 ± 0.31  100.6 ± 0.22  102 ± 0.2  101 ± 0.18 
%CDR  96.0  96.7 97.5 97.1 
 
(b) Post Compression Parameters of Tablets (F5 – F8, FSP) of Sublimation Method 
F5 (mg)  F6 (mg)  F7 (mg)  F8 (mg)  FSP(mg) 
0.602 ± 0.008  0.601 ± 0.010  0.602 ± 0.008  0.599 ± 0.008  0.602 ± 0.13 
3.15 ± 0.05  3.1 ± 0.24  3.2 ± 0.1  3.15 ± 0.11  3.15 ± 0.07 
4.5 ± 0.38    4 ± 0.25  4 ± 0.21  4.5 ± 0.33  3.75 ± 0.21 
0.15 ± 0.11  0.25 ± 0.06  0.24 ± 0.21  0.19 ± 0.27  0.30 ± 0.24 
9.71 ± 0.27  7.5 ± 0.16  8.5 ± 0.1  7.93 ± 0.36  8.0 ± 0.14 
22.5 ± 0.19  16.4 ± 0.27  18 ± 0.19  16.7 ± 0.09  11.9 ± 0.32 
77.5 ± 0.31  80.2 ± 0.22  81.4 ± 0.19  81.1 ± 0.17  84.7 ± 0.20 
24 ± 0.19  17 ± 0.31  19 ± 0.26  18.4 ± 0.1  19 ± 0.13 
98 ± 0.25  99 ± 0.3  102 ± 0.22  97 ± 0.15  102 ± 0.11 
96.8 97.7 97.1 97.0 97.1 
 
5.4. Optimization results 
5.4.1.  Effect of formulation variables on Hardness (R1) 
The models were found to be significant with F value of 129.88 and P value of 0.0002. 
In this case A, C are significant model terms and  The model describing the hardness (R1) can 
be written as : 
R1 = +5.27214+0.042857 * A-0.025000* B-0.24062  * C 
As the conc of starch increases, hardness also increases. As the conc of SSG and 
camphor increases the hardness decreases. Figure 4 represents the observed response values 
compared to that of predicted values. The effect of factors A, B and C can be further 
elucidated with the help of response surface plot Figure 5. In case of figure 5(a) factor A 
(starch) gave high value of R1 and in case of figure 5(b) high level of factor A gave high 
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value of R1 which indicates that the factor A have significant positive effect on hardness.  
Figure 4: Correlation between actual and predicted values for hardness (R1) 
 
Figure 5: Response surface plots showing the effect of (a) SSG and starch (b) camphor and 
starch on hardness (R1) 
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5.4.2.  Effect of formulation variables on Disintegration time 
The terms R2 of the model were found to be significant with an F value of 21.58 and P 
value of 0.0062. In this case A, B, C are significant model terms and  The model describing 
the disintegration time (R2) can be written as : 
R2 = +12.42262+0.060714 * A-0.22292 * B-0.40000 * C 
As the conc of starch increases, D.T also increases, as the conc of S.S.G,L-H.P.C 
increases causes the decreases the D.T. Figure 6 represents the observed response values 
compared to that of predicted values. The effect of factors A, B and C can be further 
elucidated with the help of response surface plot Figure 7.In case of figure 7(a) at high factor 
B (SSG) gave low value of R2 at all levels of factor A (Starch) and in case of figure 7(b) high 
level of factor c(camphor) gave low value of R2 at all the levels of factor A which indicates 
that the factor B,C have significant negative effect on disintegration time.  
Figure 6. Correlation between actual and predicted values for disintegration time (R2) 
 
Figure 7: Response surface plots showing the effect of (a) SSG and starch (b) camphor and 
starch on disintegration time (R2) 
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5.4.3.  Effect of formulation variables on Friability 
The terms R3 of the model were found to be significant with an F value of 64.68 and P 
value OF 0.0008. In this case A, C are significant model terms. and  The model describing the 
friability (R3) can be written as : 
R3 = +0.018393-8.70536E003*A +4.68750E003*B + 0.044531 * C 
As the conc of starch increases, friability also increases, as the conc of S.S.G,L-H.P.C 
increases causes the decreases the friability. Figure 8 represents the observed response values 
compared to that of predicted values. The effect of factors A, B and C can be further 
elucidated with the help of response surface plot Figure 9.In case of figure 9(a) factor A 
(starch) gave low value of R3 at all levels of factor B (SSG) and in case of figure 9(b) high 
level of factor A gave low value of R3 at all the levels of factor C(camphor) which indicates 
that the factor A have significant negative effect on friability.  
Figure 8: Correlation between actual and predicted values for friability (R3) 
 
Figure 9: Response surface plots showing the effect of (a) SSG and starch (b) camphor and 
starch on friability (R3) 
 
The ANOVA in Table 6 for the dependent (response) variables demonstrates that the 
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model was significant for all response variables. 
Table 6. Analysis of Variance for Dependent Variables from Factorial Design 
Source  Sum        square  d.f 
Mean     
square  F value  Probability 
Hardness kg/cm2 
R2=0.9898 
A- starch  0.46  1  0.46  107.16  0.0005 
B- S.S.G  0.029  1  0.029  6.7  0.0608 
C-L-H.P.C 1.19  1  1.19  275.77  <  0.0001 
Disintegration time sec 
R2=0.9418 
A- starch  0.92  1  0.92  9.22  0.0385 
B- S.S.G  2.29  1  2.29  22.84  0.0088 
C-L-H.P.C 3.28  1  3.28  32.69  0.0046 
Friability (%) 
R2=0.9798 
A- starch  0.019  1  0.019  60.84  0.0015 
B- S.S.G  1.01E-03  1  1.01E-03  3.24  0.1462 
C-L-H.P.C 0.041  1  0.041  129.96  0.0003 
 
Hence, the above results lead us to believe that concentrations of disintegrant and 
subliming agent have an important role to play, and optimal concentrations in fast dissolving 
tablets give rise to rapid disintegration times, good crushing strength values, and sufficiently 
low friability percentages, in order to successfully withstand the mechanical stress, during 
packing, transportation and handling. 
6.  Optimized formula: 
A numerical optimization technique, focused on the desirability approach, was used to 
generate the optimum settings for the most effective formulation. The objective in the design 
of the process was to optimize the dependent (response) variables R1, R2, R3.The optimized 
formulation obtained was included in Table 2. The optimized formulation was prepared and 
evaluated for the various responses. The optimized results obtained were included in Table 4, 
5. The results in Table 7 showed a good relationship between experimental and predicted 
values, which confirms the practicability and validity of the model. 
Table 7. Comparison between the experimental (E) and predicted (P) values for the most 
probable optimal formulation 
 
      Dependable variables 
Optimized 
formulation 
 
Hardness 
R1 
(kg/cm2) 
Disintegration time 
R2 
(sec) 
% friability R3 
(%w/w) 
Pred. 3.66  7.2  0.29 
Exp. 3.75  8  0.3 
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7.  Stability Studies 
  The stability studies of optimized formula were carried out at 40 
0C and 75% RH 
using stability chamber for six months. The different parameters that were studied are 
disintegration time, hardness, friability, drug content and dissolution rate.
24, 25 the optimized 
formulation was found to be stable in terms of physical appearance, drug content, 
disintegration time and in vitro drug release in Table 8. 
Table 8.  Stability Studies for optimized formula of Sublimation method (FSP) 
Parameters Initial  At 40 
0C and 
75% RH 
Shape Round  Round 
colour   White  White 
Odor Orange  Orange 
Weight Variation  0.602 ± 0.13  0.597± 0.05 
Thickness(mm)  3.15 ± 0.07  3.15 ± 0.15 
Hardness (kg/cm2)  3.75 ± 0.21  3.75 ± 0.08 
Friability (%w/w)  0.30 ± 0.24  0.30 ± 0.07 
Disintegration time (sec)  8.0 ± 0.14  8.4 ± 0.10 
Wetting time (sec)  11.9 ± 0.32  12.0 ± 0.08 
Water absorption ratio (%)  84.7 ± 0.20  84.9 ± 0.31 
In vitro dispersion time (sec)  19 ± 0.13  19.5 ± 0.10 
% Drug content  102 ± 0.11  102 ± 0.05 
%CDR 97.1  97.1 
 
 
8.  Conclusion 
The results of a 2
3 full factorial design revealed that the amount of camphor, starch 
and sodium starch glycolate significantly affect the dependent variables such as disintegration 
time, hardness and percentage friability. Thus it is concluded that by adopting a systematic 
formulation approach, an optimum point can be reached in the shortest time with minimum 
efforts. Sublimation technique would be an effective alternative approach compared with the 
use of more expensive adjuvant in the formulation of fast dissolving tablets.  
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